期刊文献+

多发性骨髓瘤中MAPK信号通路对BLyS表达的调控研究 被引量:4

The regulation of BLyS expression levels through MAPK signal pathway in multiple myeloma
原文传递
导出
摘要 目的 研究多发性骨髓瘤(MM)细胞中丝裂原活化蛋白激酶(MAPK)信号通路的表达及活化情况,探讨MAPK信号通路对MM细胞B淋巴细胞刺激因子(BLyS)表达变化的影响及对MM细胞增殖与存活的影响,并初步探讨MAPK信号通路在IFN-γ(MM重要的促生长因子)上调MM细胞BLyS表达过程中的作用.方法 应用Western blot方法检测MM细胞中蛋白ERK、p-ERK、JNK、p-JNK、p38及p-p38的表达情况;应用RT-PCR及Western blot检测MAPK信号通路对BLyS表达的影响;应用WST-1法检测靶向JNK的MAPK信号通路抑制剂SP600125对MM细胞增殖与存活的影响.结果 MM细胞株中,除了ERK、JNK及p38的表达外,还有活化蛋白p-JNK的表达;靶向JNK的MAPK信号通路抑制剂SP600125可下调MM细胞BLyS的表达,其激动剂茴香霉素(anisomycin)可上调BLyS的表达;IFN-γ可上调MM细胞BLyS的表达,SP600125可部分抵消IFN-γ对BLyS的上调作用;SP600125可抑制MM细胞的增殖与存活.结论 MM细胞中有JNK/SAPK信号通路的活化;JNK/SAPK信号通路的活化程度与BLyS的表达高低呈正相关;JNK/SAPK信号通路在IFN-γ上调MM细胞BLyS表达过程中发挥重要作用. Objective To investigate the activation of MAPK signal pathway in multiple myeloma and the regulation of BLyS expression levels through MAPK signal pathway; preliminarily study the role of MAPK signal pathway in the up-regulation of BLyS expression levels induced by IFN-γ.Methods Activated MAPK pathway were detected by Western blot,while the expression of BLyS were detected with RT-PCR and Western blot,and Western blot investigated the effect of MAPK pathway on BLyS expression levels induced by IFN-γ.Results In addition to the expression of ERK,JNK,p38,p-JNK was also expressed in MM cell lines,the MAPK pathway inhibitor targeting JNK SP600125 can down-regulate the expression of BLyS,and its activator anisomycin can up-regulate the expression of BLyS.SP600125 restrained the proliferation and survival of MM cells.Conclusion JNK/SAPK pathway was activated in MM cells; The activated degree of JNK/SAPK pathway and the expression level of BLyS was positively correlated.JNK/SAPK pathway play an important role in the up-regulation of BLyS expression levels induced by IFN-γ.
出处 《中华微生物学和免疫学杂志》 CAS CSCD 北大核心 2011年第12期1081-1086,共6页 Chinese Journal of Microbiology and Immunology
基金 江苏省六大人才高峰项目(2008095) 江苏省自然科学基金(BK2010284)
关键词 多发性骨髓瘤(MM) B淋巴细胞刺激因子(BLyS) MAPK信号通路 Multiple myeloma B-lymphocyte stimulator (BLyS) MAPK signal pathway
  • 相关文献

参考文献2

二级参考文献22

  • 1鞠少卿,张冬雷,倪红兵,王跃国,苏建友,施健,王惠民,孔宪涛,仲人前.实时荧光定量测定人B细胞激活因子受体基因表达水平[J].中华检验医学杂志,2005,28(3):299-301. 被引量:3
  • 2张冬雷,施健,王惠民,鞠少卿,崔之础,倪红兵.系统性红斑狼疮患者B细胞激活因子mRNA定量测定及其意义[J].临床检验杂志,2005,23(3):186-188. 被引量:5
  • 3张冬雷,鞠少卿,施健,王惠民,王跃国,倪红兵,孔宪涛,仲人前.人B细胞激活因子受体-TACI基因表达水平的定量测定[J].中国免疫学杂志,2006,22(4):333-336. 被引量:3
  • 4沈荣春,鞠少卿,王跃国,丛辉,徐云.实时荧光定量测定人B细胞激活因子受体-BCMA基因表达水平[J].陕西医学杂志,2006,35(11):1503-1505. 被引量:2
  • 5Moore PA, Belvedere O, Orr A, et al. Blys.. member of the tumor necrosis factor family and B lymphocyte stimulator[J]. Science, 1999,285 : 260-263.
  • 6Novak AJ,Darce JR,Arendt BK,et al. Expression of BCMA,TACI and BAFF-R in multiple myeloma:a mechanism for growth and survival[J]. Blood, 2004, 103:689-694.
  • 7O'Connor BP,Raman VS,Erickson LD,et al. BCMA is essential for the survival of long-lived bone marrow plasma cells[J]. J Exp Meal,2004,199:91-98.
  • 8Klein U, Rajewsky K, Kuppers R. Human immunoglobulin IgM + IgD+ peripheral blood B cells expressing the CD27 cell surface antigen carry somatically mutated variable region genes:CD27 as a general marker for somatically mutated (memory) B cells[J]. J Exp Med, 1998,188 : 1679-1689.
  • 9Tarte K,De Vos J,Thykjaer T,et al. Generation of polyclonal plasmablasts from peripheral blood B cells: a normal counterpart of malignant plasmablasts [J]. Blood, 2002,100 : 1113-1122.
  • 10Tarte K,Zhan F,De Vos J,et al. Gene expression profiling of plasma cells and plasmablasts :toward a better understanding of the late stages of B-cell differentiation[J]. Blood, 2003,102 : 592-600.

共引文献10

同被引文献51

  • 1Finn RS. Development of molecularly targeted therapies in hepato- cellular carcinoma: where do we go now?. Clin Cancer Res, 2010, 16(2): 390-397.
  • 2Klebanoff CA, Acquavella N, Yu Z, et al. Therapeutic cancer vaccines: are we there yet? Immunol Rev, 2011, 239 (1): 27- 44.
  • 3Sah NK, Khan Z, Khan GJ, et al. Structural, functional and therapeutic biology of survivin. Cancer Lett, 2006, 244 ( 2 ) : 164-171.
  • 4Honma I, Kitamura H, Torigoe T, et al. Phase I clinical study of anti-apoptosis protein survivin-derived peptide vaccination for pa- tients with advanced or recurrent urothelial cancer. Cancer Immu- nol Immunother, 2009, 58( 11 ) : 1801-1807.
  • 5Yu Z, Theoret MR, Touloukian CE, et al. Poor immunogenicity of a self/tumor antigen derives from peptide-MHC-I instability and is independent of tolerance. J Clin Invest, 2004, 114 (4) : 551- 559.
  • 6Bachinsky MM, Guillen DE, Patel SR, et al. Mapping and bind- ing analysis of peptides derived from the tumor-associated antigen survivin for eight HLA alleles. Cancer Immun, 2005, 5 : 6.
  • 7Colella TA, Bullock TN, Russell LB, et al. Self-tolerance to the murine homologue of a tyrosinase-derived melanoma antigen: im- plications for tumor immunotherapy. J Exp Med, 2000, 191 (7) : 1221-1232.
  • 8Rizzuto GA, Merghoub T, Hirschhom-Cymerman D, et al. Self- antigen-specific CD8 T cell precursor frequency determines the quality of the antitumor immune response. J Exp Med, 2009, 206(4) : 849-866.
  • 9Yamamoto H, Ngan CY, Monden M. Cancer cells survive with survivin. Cancer Sci, 2008, 99(9) : 1709-1714.
  • 10孙裕昌,沈娟,沈晗,邵红伟,黄树林.Hela细胞Survivin克隆及HLA-A2限制性CTL表位预测研究[J].中国免疫学杂志,2007,23(11):1044-1047. 被引量:2

引证文献4

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部